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Abstract
OBJECTIVES: Aneurysm diameter and growing rate does not represent a deﬁnite parameter for operation in bicuspid aortic valve (BAV),
ascending aortic aneurysm and normal root patients. Thus, we investigated histological and immunohistochemical aspects of different
segments of ascending aorta (precisely, aortic root without dilatation, aneurysmatic tubular portion, dissected ascending aorta) and
genetic features of patients with BAV and ascending aorta complication (aneurysm or dissection).
METHODS: Aorta tissue samples of 24 BAV patients were examined. The patients comprised of 18 men and 6 women; the mean age
was 54.2 ± 14.3 years. All patients underwent composite aortic root replacement (button Bentall operation). Multiple histological sec-
tions were prepared from each aortic specimen. The evaluated features included elastic ﬁbre fragmentation, cystic medial change,
smooth muscle cell necrosis, medial ﬁbrosis, and the markers of medial apoptosis and the metalloproteinases. Furthermore, genetic
risk factors were also investigated.
RESULTS: The same medial degenerative lesions in tissue samples of different aorta segments (precisely of aortic root without dilata-
tion, and aneurysmatic ascending aorta portion) were observed. More signiﬁcant associations between single nucleotide polymorph-
isms (−786T/C endothelial nitric oxide synthase enzyme, D/I angiotensin-converting enzyme, −1562C/T metalloproteinase-9 and
−735C/T metalloproteinase-2) and aneurysm risk were detected in BAV patients than in controls.
CONCLUSIONS: Based on our histological and genetic data, we underline that a surgical approach in patients with BAV, ascending
aortic aneurysm and normal root, should consider not only the diameter of the aneurysmatic aortic portion but also the histological
features of the whole ascending aorta and the genetic risk proﬁle.
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INTRODUCTION
Bicuspid aortic valve (BAV) is one of the most frequent congeni-
tal heart defects having a prevalence of 0.5–1.4%. It appears to
be sporadically transmitted through families by an autosomal-
dominant pathway, with a 3:1 male predominance [1–3].
Pathogenesis is considered as a very complex development
process [4–6].
BAV is frequently (10–35% of cases) associated with an en-
largement of ascending aorta [7] and its severe complications
such as aortic rupture or dissection. Case dissections associated
with BAV are about 4% [8]. Different, controversial theories have
been suggested to explain the strong association between BAV
and ascending aorta aneurysm and dissection [9, 10].
Because ascending aorta dilatation is a widely recognized risk
factor for aortic dissection [11], a more aggressive posture
towards replacement of the moderately enlarged ascending
aorta has been advocated in the most recent American College
of Cardiology/American Heart Association guidelines for the
treatment of patients with thoracic aortic disease [12].
Some authors propose a more radical resection of the aorta
because of the potential development of a late dilatation and
dissection in the remaining distal ascending aorta and aortic
root with or without a mild dilatation [13, 14].
Based on this evidence, we suggest that the diameter of
aneurysmatic aortic portion is not the unique parameter to con-
sider for operation on patients with BAV and aneurysm. Thus,
the histological features of complete ascending aortic wall
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(inclusive aortic root without dilatation) and the genetic risk
proﬁle should also be considered.
To conﬁrm this hypothesis, we examined histopathological
features of different ascending aorta segments (precisely, aortic
root without dilatation, aneurysmatic tubular portion, dissected
ascending aorta) in aorta tissue samples of 24 BAV patients with
ascending aorta complication (aneurysm or dissection) who
underwent cardiac surgery between January 2004 and July 2008
in our Cardiac Surgery Unit. Furthermore, the role of genetic
component in the susceptibility and risk for ascending aorta an-
eurysm and dissection in BAV patients was also evaluated.
MATERIALS AND METHODS
Our study received approval from local ethic committees and all
participants gave their informed consent. Data were encoded to
ensure patient and control protection.
Subjects
Our study included 24 BAV individuals [18 men (75%) and 6
(25%) women; mean age: 54.2 ± 14.3] from Western Sicily. They
were registered between January 2004 to July 2008 at the
Cardiac Surgery Unit of the Surgery and Oncology Department
of Palermo University Hospital. We selected BAV patients with
aortic complications [23 (96%) aneurysms and 1 (4%) dissection]
and not dilated aortic root. All patients showed qualitatively
altered aortic root at the time of operation: thin and weak walls
with graining. BAV (stenotic or incontinent) was ﬁbrocalciﬁc in
13 (54%) cases and prolapsed in one (4%) case (Table 1).
Diameter evaluation of ascending aorta was made both pre-
operatively and in the operating room by transthoracic echocar-
diography (TTE) and transesophageal echocardiography (TEE)
estimations performed as follows: estimating dimensions of
aortic annulus, sinuses of Valsalva and proximal ascending aorta
(above 2.5 cm of the sinotubular junction) in parasternal long
axis; evaluating the ones of aortic arch from suprasternal view.
Echocardiography derived sizes were reported as internal diam-
eter size [15]. Sinus of Valsalva mean size was 34 ± 3.0 mm in
men and 30 ± 3.0 mm in women (Table 1). Aneurysmatic ascend-
ing aorta mean size was 50 ± 5.6 in men and 58 ± 16 mm in
women (Table 1). Colour Doppler was used to assess the pres-
ence and severity of aortic regurgitation and stenosis.
Furthermore, aortic root and ascending aorta diameter sizes
were carried out using helical computed tomography image
analysis techniques. Relevant medical histories regarding aortic
disease were obtained from patients’ medical records.
Thus, demographic and clinical features, comorbidity condi-
tions and pharmacological treatments were collected (Table 1).
In particular, our patients had suffered from hypertension for a
few years. In all cases, hypertension was controlled by
beta-blockers.
The surgical procedure used was the button Bentall operation,
which is a modiﬁcation of the original technique described by
Kouchoukos et al. 1991 [16]. In order to detect histopathological
abnormalities, control ascending aortas were obtained from 30
individuals (20 men and 10 women; mean age: 55 ± 11.57 years)
who died from causes unrelated to aortic disease and with no
sepsis at the time of death, as conﬁrmed by autopsy.
One hundred and twenty-eight matched controls [61 (47%)
men and 67 (53%) women; mean age: 61.08 ± 5.83 years] were
also enrolled to perform genotype analyses. They were in good
health, according to their clinical history and blood tests (com-
plete blood cell count, erythrocyte sedimentation rate, glucose,
urea nitrogen, creatinine, electrolytes, C-reactive protein, liver
function tests, iron and proteins). None had any other major
cardiac risk factors, with the exception of smoking (23%).
Furthermore, TTE imaging examinations conﬁrmed the absence
of ascending aorta aneurysms, BAV and aortic valve dysfunction
in all controls. We selected a very homogenous population. As a
matter of fact, all patients and controls belonged to the same
ethnic group, as their parents and grandparents were born in
Western Sicily.
Aortic specimens and histopathological assays
Full aortic segments were collected from resected aortic wall of 24
patients at the time of surgery and ﬁxed in 10% neutral buffered
Table 1: Demographics and preoperative clinical
characteristics
Variables Patients
(n = 24)
Women
(n = 6)
Men
(n = 18)
P-value
Demographic characteristics
Age, mean (SD) 54.2 (14.3) 56.3 (13) 53.5 (15) 0.46
Male sex, no .(%) 18 (75%)
Female sex, no. (%) 6 (25%)
Body mass index, mean
(SD)
27 (3.1) 27.4 (4.8) 26.9 (2.5) 0.92
Size (echocardiographic value)
Proximal ascending
aorta size (mm), mean
(SD)
52.3 (9.4) 58 (16) 50 (5.6) 0.15
Sinus of Valsalva size
(mm), mean (SD)
33 (3.8) 34 (3.0) 30 (3.0) 0.001
Comorbidity conditions, no. (%)
Aortic aneurysm
familiarity
1 (4) 0 (7.1) 1 (7.9) 1.00
Cardiovascular ischaemic
familiarity
9 (38) 2 (35.7) 7 (39.4) 1.00
Smoke 8 (33) 0 (7.1) 8 (44.7) 0.05
Hypertension 18 (75) 6 (92.8) 12 (65.8) 0.28
Dislipidaemia 4 (17) 0 (7.1) 4 (23.7) 0.54
Diabetes mellitus 1 (4) 0 (7.1) 1 (7.9) 1.00
Renal failure 1 (4) 0 (7.1) 1 (7.9) 1.00
Aortic valve pathology, no. (%) 1.00
Normal 10 (42) 3 (46.7) 7 (53.8)
Prolapse 1 (4) 0 (6.6) 1 (7.7)
Vascular calcium fibrosis 13 (54) 3 (46.7) 10 (38.5)
Aortic valve dysfunction, no. (%) 0.26
Normal 3 (13) 2 (29.4) 1 (7.3)
Faint incontinence 9 (38) 1 (17.7) 8 (41.4)
Moderate incontinence 1 (4) 0 (5.8) 1 (7.3)
Severe incontinence 0 (0) 0 (0) 0 (0)
Faint stenosis 0 (0) 0 (0) 0 (0)
Moderate stenosis 2 (8) 1 (17.7) 1 (7.3)
Severe stenosis 9 (38) 2 (29.4) 7 (36.6)
Atherosclerosis coronary
syndrome, no. (%)
11 (46) 4 (64.3) 7 (39.5) 0.36
SD, standard deviation; No., number of patients.
A
O
R
TI
C
A
N
D
A
N
EU
R
Y
SM
A
L
C. Pisano et al. / Interactive CardioVascular and Thoracic Surgery 301
formalin for 24 h and then processed for routine parafﬁn embed-
ding. Multiple histological sections from each sample were pre-
pared and stained with haematoxylin–eosin, Weigert-van Gieson,
Alcian-PAS for microscopic examinations. Histopathological abnor-
malities of aortic wall media were graded and deﬁned according to
the deﬁnitions and grading systems used by Bechtel et al. [17].
Serial sections of these tissues were also used for immunohis-
tochemical staining. The aortic wall was mainly evaluated for the
following histological features: elastic ﬁbre fragmentation and
collagen ﬁbre network, presence of necrosis, apoptosis, amounts
of metalloproteinase-9 (MMP-9) and inﬂammatory cell
inﬁltration.
Immunohistochemical assays
Immunohistochemical analyses were performed on 5 µm-thick
parafﬁn-embedded sections. The deparafﬁnized sections were
treated for 20 min in a microwave oven in 10 mM citrate buffer
of pH 6 or Tris–EDTA of pH 9. Sections were then incubated for
1 h with speciﬁc monoclonal antibodies against MMP-9 (Clone
15W2, NCL-MMP9 439, Novocastra Laboratories Ltd, UK, 1:50),
or isotype-matched controls at appropriate dilutions. After
washing in TBS 1X (Tris-buffered solution), staining was per-
formed by biotinylated link antibody and streptovidin labelled
with PEROXIDASE KITS (Dako, North America, Inc, USA) and it
was detected using AEC (3-amino-9-ethylcarbazole) substrate
chromogen. After that, the counterstaining of cells and tissue
sections was performed using aqueous haematoxylin
(Novocastra Laboratories Ltd).
Tunel testing
We performed TdT (Terminal deoxynucleotidyl Transferase)-
mediated X-dUTP (deoxyuridine triphosphate nucleotides) nick
end-labelling (TUNEL) reaction (‘In situ cell death detection kit’,
Roche Diagnostics S.p.A, Milano, Italy) on full-thickness aortic wall
parafﬁn sections (5 µm). Tissues were deparafﬁnized and then
permeabilized with PBS, 0.1% sodium citrate/0.1% Triton X-100.
Specimens were then incubated with TdT and ﬂuorescein-
labelled dUTP in a humidiﬁed atmosphere for 1 h at 37°C. In situ
apoptosis staining was revealed by using an AP converter.
DNA strand breaks were detected using the 5-bromo-4chloro-
3-indolyl-phosphate (BCIP/NBT, Dako, Italy) substrate chromo-
gen. Tissues were subsequently counterstained with eosin under
light microscopy.
Semi-quantitative evaluation of MMP-9
by immunohistochemical assays
A semi-quantitative evaluation of MMP-9 amount in aortic spe-
cimens of 24 patients was performed during the course of
immunohistochemical assays. Staining was classiﬁed as faint,
moderate or severe.
Genotyping
DNA samples of 24 cases and 128 matched controls were
extracted from peripheral blood samples collected in tripotas-
sium EDTA and puriﬁed using a QIAamp Blood DNA Maxi kit
(Qiagen, Dusseldorf, Germany). Samples were genotyped for 10
single nucleotide polymorphisms (SNPs) located in the promoter
and coding regions of selected genes (Table 2). Two procedures
were used, such as restriction fragment length polymorphism–
PCR (RFLP–PCR) and single speciﬁc primer (SSP)–PCR.
For genotyping +896A/G (Asp299Gly, rs4986790), +1196C/T
(Thr399Ile, rs4986791), Toll-like receptor 4 (TLR4) SNPs and Δ32
C-C chemokine receptor type 5 (CCR5) deletions (rs333), proce-
dures previously described were used [18–21].
For identiﬁcation of −1562C/T MMP9 (rs3918242), −1306C/T
(rs243865) and −735C/T MMP2 (no rs available designation)
SNPs, RFLP–PCR procedure was used, followed by restriction
cleavage with ShpI, AccI and HinfI (New England Biolabs, USA),
respectively, and separation of DNA fragments by electrophor-
esis. For genotyping +894G/T (Glu208Asp, rs1799983) and
Table 2: Genes (accession number), SNPs (accession number) and substitutions investigated in the study
Genes SNPs Biological effect
TLR4 (NM-138554.1) +896A/G (Asp299Gly; rs4986790) Determining a single amino acid substitution in the extracellular receptor domain and hence,
a blunted innate/inflammatory response to both foreign pathogens and endogenously
generated inflammatory ligands
+1196C/T (Thr 399Ile; rs4986791)
CCR5 (NM-00579) Deletion 32 (rs333) A non-functional allele resulting from a 32-bp deletion in exon 4 (CCR5_32) determines a
loss of expression of functional CCR5 receptor
MMP9 (NM-004985) −1562C/T (rs3918242) Located within a putative binding site for a regulator factor of the gene transcription,
determining an increased expression of MMP-9 enzyme
MMP2
(NM-001121363.1)
−1306C/T (rs243865) They are located within a putative binding site for a regulator factor, Sp1, of the gene
transcription, determining an increased expression of MMP-2 enzyme−735C/T (rs 2285053)
eNOs (NM-000594) 894G/T (Glu208Asp; rs 1799983) Determining a single amino acid substitution (Glu/Asp-208), associated with a reduced basal
production of eNOs and an increased amount of plasmatic homocysteine
−786T/C (rs2070744) SNP located in the promoter region determining a reduced gene transcription
4a/4b VNTR repeat A VNTR repeat of 27 bp in a intron region associated with an altered production of eNOs
ACE (NM-152830.1) D/I SNP (rs1799752) Determining changes in the plasmatic and cellular concentration of ACE enzyme. The D allele
is associated with a high risk and susceptibility of vascular disorders
TRL, Toll-like receptor 4; CCR, C-C chemokine receptor type 5; MMP-2 and -9, metalloproteinase 2 and 9; eNOs, endothelial nitric oxide synthase
enzyme; ACE, angiotensin-converting enzyme; VNTR, variable number tandem repeats.
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−786T/C (rs2070744) SNPs in endothelial nitric oxide synthase
enzyme (eNOs) gene, RFLP–PCR was also executed, followed by
restriction cleavage with BanI and NaeI (New England Biolabs),
respectively, and separation of DNA fragments by electrophor-
esis. Meanwhile, an SSP–PCR was assessed for genotyping 4a/4b
eNOs and D/I (rs1799752) angiotensin-converting enzyme
(ACE) SNPs.
Statistical analysis
All analyses were performed with R and EXCEL software. Fisher
tests were conducted to compare all demographic and clinical
features, comorbidity conditions and pharmacological treat-
ments according to gender, and also to verify the hypothesis of
association between elementary lesions and valvular dysfunction.
To verify the hypothesis of a relationship between the size of an
aneurysm and an elementary lesion, non-parametric Kruskal–
Wallis tests were executed; this is due to the strong asymmetry
of the size distributions. To analyse signiﬁcantly the relationships
between quantitative variables, the Wilcoxon rank sum test was
employed. Allele and genotype frequencies were evaluated by
gene count. Data were tested for ﬁnding out the consistency
between observed and expected genotype frequencies, accord-
ing to Hardy–Weinberg equilibrium, by χ2-tests. Signiﬁcant dif-
ferences in frequencies among groups were calculated by using
χ2-test and appropriate tables (3 × 2, 2 × 2 tables, etc. wherever
appropriate). Furthermore, odds ratios (OR) with 95% conﬁdence
intervals (CI) and their signiﬁcance were calculated.
RESULTS
Clinical data
Table 1 reports demographic and clinical features, comorbidity
conditions and pharmacological treatments of all BAV patients.
Considering the elevated number of men affected by BAV asso-
ciated to aneurysms (18 vs. 6 women), comparisons of all demo-
graphic and clinical features, comorbidity conditions and
pharmacological treatments were performed depending on
gender. No statistically signiﬁcant differences were detected
with the exception of smoking (8 males vs. 0 female, P = 0.05 by
Fisher test).
Hospital mortality and short-term outcome
Hospital mortality—deﬁned as in hospital mortality or death
within the postoperative 30 days—was 0%. Bleeding occurred in
just 1 case. One patient required prolonged ventilation. The
average intensive care stay unit was 2.5 ± 2 days, and the mean
hospital stay was 10 ± 2 days.
Histological and immunohistochemical
observations
Histological and immunohistochemical assessments evidenced
the presence of media-degenerative lesions in tissue samples of
the aortic wall both of aneurysmatic or dissected tubular portion
and aortic root without dilatation. In particular, we observed:
elastic fragmentation of grade I in ﬁve cases (21%), grade II in 13
cases (54%) and grade III in six cases (25%); medionecrosis of
grade I in three cases (13%), grade II in 11 cases (46%) and
grade III in 10 cases (41%); cystic necrosis of grade I in four cases
(17%), grade II in 13 cases (54%), grade III in seven cases (29%);
medial ﬁbrosis: grade I in 17 cases (70%), grade II in three cases
(13%), grade III in one case (4%) (Fig. 1).
No signiﬁcant associations were observed between aortic
valve dysfunction, with or without cuspid pathological lesions,
and medial change severity (P-value > 0.05 by Fisher test; data
not shown). Apoptosis of media smooth muscle cells (SMCs) was
found in 23 cases (96%); it was plurifocal in 18 cases (75%), and
focal in ﬁve cases (21%). The research of collagenases in aortic
media revealed the presence of MMP-9 in all cases with a differ-
ent concentration (faint: three cases, 13%; moderate: nine cases,
37%; severe: 12 cases, 50%) and localization (intramyocitic
pattern; interstitial pattern; intramyocitic and interstitial pattern).
Figure 1: Media-degenerative lesion distribution in BAV patients with aortic complications (aneurysm and dissection).
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Genotype distributions and allele frequencies
of the ten SNPs
Comparing genotype distributions and allele frequencies of 10
SNPs selected among 24 BAV patients and 128 matched con-
trols, some signiﬁcant differences were observed for following
SNPs: −786T/C eNOs, D/I ACE, −1562C/T MMP-9 and −735C/T
MMP-2 (Table 3). In particular, we observed that −786T/T eNOS
genotype was signiﬁcantly represented in 24 BAV patients than
128 matched controls (P = 0.02 by χ2-test 3 × 2 table).
Furthermore, out of 128 patients, nobody presented −786C/C
genotypes. In contrast, 4% and 33% of control group were car-
riers of mutant variant, associated with a decreased expression
of eNOs molecule as indicated in Table 2. In addition, −786T
allele was signiﬁcantly over-represented in patients with respect
to controls (P = 0.01 by χ2-test with Yates’s correction, 2 × 2
table; OR = 0.17 (0.04–0.7) P = 0.006 by Fisher’s exact test).
A signiﬁcant difference in genotype distribution of D/I ACE
SNP was found among 24 BAV patients and 128 matched con-
trols (P = 0.01 by χ2-test 3 × 2 table). Accordingly, D ACE variant
was signiﬁcantly over-expressed in patients compared with con-
trols (P = 0.02 by χ2-test with Yates’s correction, 2 × 2 table; OR =
3.3 (1.6–6.5) P = 0.0005 by Fisher’s exact test).
Furthermore, we found that −1562T/T MMP-9 was signiﬁcant-
ly represented in 24 BAV patients than in 128 matched controls
(P = 0.0005 by χ2-test 3 × 2 table; Table 3). Accordingly, −1562T
MMP-9 allele was signiﬁcantly over-represented in patients with
respect to controls (P = 0.00001 by χ2-test with Yates’s correction,
2 × 2 table; OR = 5.9 (2.6–13.5) P < 0.0001 by Fisher’s exact test).
The same results were obtained for −735C/T MMP-2. Precisely,
−735T/T genotype was signiﬁcantly represented in 24 BAV
patients than in 128 matched controls (P = 0.0005 by χ2-test;
3 × 2 table; Table 3). Accordingly, −735T MMP-2 allele was
signiﬁcantly over-represented in patients with respect to controls
(P = 0.0001 by χ2-test with Yates’s correction, 2 × 2 table; OR =
8.5 (2.5–28.2) P = 0.0007 by Fisher’s exact test).
Long-term outcome
Median follow-up time was 4.5 years. No patient required
ascending aortic reoperation. None has died. They manage
normal daily activities without any limitations.
DISCUSSION
A high incidence of both ascending aorta aneurysm and Stanford
type A dissection and a high risk for aorta-related death (rupture
or dissection) have been evidenced in BAV patients [8]. The high
tendency for ascending aortic aneurysm or Stanford type A dis-
section observed in BAV patients seems due to histopathological
abnormalities of the aorta wall. This evidences and the 11 times
higher incidence of Stanford type A dissection in BAV patients
than in the normal tricuspid aortic valve population, as recently
reported, underline that the intricate problem within the aortic
wall in BAV patients might involve the ascending aortic portion, as
well as the non-dilated aortic root. According to our study, al-
though based on a limited sample size, histological and immuno-
histochemical data evidenced aorta wall abnormalities (a small
amount of elastic tissue and a very signiﬁcant apoptosis and
amount of MMP-9 collagenase) in BAV patients, both in non-di-
lated aortic root and aneurysmatic ascending aorta. These fea-
tures suggest high risk even in the case of non-dilated aortic root
Table 3: Genotype distributions and allele frequencies of −786eNOs, D/I ACE, +896TLR4, −1562C/T MMP-9, −735C/T MMP-2
SNPs in 24 BAV patients and 128 matched controls (2 × 2 comparisons between the different groups with odd ratio (OR) and
95% confidence interval)
Candidate
genes
Reference SNP number Candidate
SNPs
Patients (n = 24)
(%)
Matched controls (n = 128)
(%)
P (3 × 2, 2 × 2
table)
OR (95% CI)
eNOS rs2070744 −786T/T 22 (92%) 81 (63%) 0.02 0.17 (0.04–0.7),
P = 0.006−786T/C 2 (8%) 42 (33%)
−786C/C 0 (0%) 5 (4%)
−786T 46 (96%) 204 (80%) 0.01
−786C 2 (4%) 52 (20%)
ACE rs1799752 I/I 6 (25%) 70 (55%) 0.01 3.3 (1.6–6.5),
P = 0.0005D/I 1 (4%) 1 (1%)
D/D 17 (71%) 57 (44%)
I 13 (27%) 141 (55%) 0.02
D 35 (73%) 115 (45%)
MMP-9 rs3918242 −1562C/C 15 (63%) 116 (90%) 0.0005 5.9 (2.6–13.5),
P < 0.0001−1562C/T 5 (21%) 9 (8%)
−1562T/T 4 (16%) 3 (2%)
−1562C 35 (73%) 241 (94%) 0.00001
−1562T 13 (27%) 15 (6%)
MMP2 (no rs designation
available)
−735C/C 18 (75%) 123 (96%) 0.0005 8.5 (2.5–28.2),
P = 0.0007−735C/T 5 (21%) 5 (4%)
−735T/T 1 (4%) 0 (0%)
−735C 41 (85%) 251 (98%) 0.0001
−735T 7 (15%) 5 (2%)
All genotypes were in Hardy–Weinberg equilibrium. eNOS, endothelial nitric oxide synthase enzyme; ACE, angiotensin-converting enzyme; MMP,
metalloproteinase.
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for a possible rupture and dissection. Our results lead us to
propose that, in BAV patients, the diameter of an aneurysmatic
aorta and its growing rate do not represent the only parameters
to be considered for surgical strategy. Furthermore, genetic data
should be considered. Signiﬁcant associations and a very high OR
between −786T/C eNOs, D/I ACE, −1562C/T MMP-9 and −735C/T
MMP-2 SNPs and risk for BAV were detected in the patients than
in controls. Because of the biological effects of these SNPs, their
signiﬁcant overexpression in patients suggests the capacity of de-
termining a major fragility of the aorta wall, consequently asso-
ciated with a major risk to develop severe complication, such as
aorta dissection and/or rupture. MMP-9 and MMP-2 overexpres-
sion determines an excessive elastic tissue fragmentation with a
consequent impairing of the aorta wall’s mechanical properties. It
is possible that the loss of aortic wall integrity predisposes SMCs
to a higher risk of damage and death, with the consequent loss of
the latter (medionecrosis) and replacement with mucoid basophil
substance (cystic necrosis).
Some authors recommend composite aortic root replacement
as the appropriate surgical strategy to treat and prevent these
aorta diseases in BAV patients. This surgical procedure has been
advocated to prevent ascending aortic or root dilatation [22, 23].
Therefore, the complete replacement of both the aortic root and
the ascending aorta segment might eliminate the risk of rupture
and dissection in a very large number of BAV patients. On the
other hand, Etz et al. [14] found that the Bentall operation is
associated with superior long-term survival and a lower rate of
aortic re-operation in BAV patients. Recently, Park et al. demon-
strated that a separate valve and graft remains an appropriate
procedure for some patients with BAV and ascending aortic dila-
tation without signiﬁcant root enlargement. Composite root re-
placement is a well-established procedure but it is technically
more challenging and carries risks of coronary osteal complica-
tions, including bleeding, kinking and formation of false aneur-
ysm. Owing to the frequency of aortic valve replacement (AVR)
for BAV, any unnecessary incremental increase in risk globally
applied will have a powerful clinical impact [24]. McKellar et al.
[25], in a study of 1286 patients undergoing AVR for BAV without
ascending aorta replacement, concluded that, despite a true risk
for aortic events after AVR for BAV, the occurrence of aortic
dissection is low and any incremental surgical risk imposed
by prophylactic replacement of ascending aorta must be
equally low.
Based on our results, we would suggest that the use of a
surgical procedure based on the complete removal of ascend-
ing aorta including aortic root with or without dilatation
might be reasonable in BAV patients with a high risk of
rupture and dissection, especially in BAV patients with a thin
aortic root wall at the time of operation and a particular
genetic risk proﬁle. However, our suggestion is based only on
histological and genetic features. Clinical data are required to
support them. A longitudinal study of both procedures, or a
larger series on both the techniques would be needed to
clear out the issue of the replacement, or not, of the
aortic root.
In conclusion, BAV is frequently associated with an enlarge-
ment of the ascending aorta and its severe complications such
as aortic rupture or dissection. The diameter of aneurysm and
the growing rate does not represent a deﬁnite parameter for op-
eration. Surgical strategy should also consider the structure of
the complete ascending aortic wall (the grade of medial degen-
eration) and genetic risk factors as demonstrated by our study.
Study limitations
The principle limitation of this study is the limited sample size
and the rarity of BAV pathology. Besides, clinical recommenda-
tions require clinical data to support them.
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